Neurothrombectomy Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product (Clot Retrievers, Aspiration/ Suction Devices, Vascular Snares), By End User (Hospital, Emergency Clinics, Ambulatory Surgical Centers), By Region, & Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 758.12 Million
CAGR (2026-2031)	7.09%
Fastest Growing Segment	Clot Retrievers
Largest Market	North America
Market Size (2031)	USD 1143.49 Million

Market Overview

The Global Neurothrombectomy Devices Market is projected to grow from USD 758.12 Million in 2025 to USD 1143.49 Million by 2031 at a 7.09% CAGR. Neurothrombectomy devices are specialized medical instruments designed to mechanically remove blood clots from cerebral arteries, thereby restoring blood flow in patients experiencing acute ischemic stroke. The market's expansion is fundamentally driven by the escalating global incidence of ischemic strokes, which necessitate these interventions, alongside continuous technological advancements in endovascular techniques that improve treatment outcomes. According to the European Stroke Organisation and Stroke Alliance for Europe, in 2024, the European mean for mechanical thrombectomy treatment reached 7.3% of all ischemic stroke patients.

A significant challenge impeding market growth, however, stems from the substantial capital investment required for these advanced devices and the specialized infrastructure and highly skilled neurointerventionalists necessary for their effective deployment. These factors limit broader adoption, particularly within resource-constrained healthcare systems globally.

Key Market Drivers

Rising global stroke burden drives demand
The increasing global prevalence of acute ischemic stroke represents a primary catalyst for the expansion of the neurothrombectomy devices market. As stroke incidence rises, so does the demand for effective intervention methods to mitigate disability and mortality. According to the World Stroke Organization's Global Stroke Fact Sheet 2025, there are almost 12 million new strokes each year globally, with ischemic stroke constituting 65.3% of these incidents. This substantial and ongoing burden underscores the critical need for advanced neurothrombectomy devices, as mechanical thrombectomy has become a standard of care for large vessel occlusions, driving higher procedure volumes.

Technological innovations and market momentum
Complementing this, continuous advancements in neurothrombectomy device technology are significantly influencing market growth by enhancing procedural success rates and expanding the treatable patient population. Innovations focus on improving device maneuverability, clot retrieval efficacy, and reducing procedure times. For instance, according to Rapid Medical, in April 2026, the company received U.S. Food and Drug Administration clearance for its TIGERTRIEVER 25 thrombectomy device, designed to address challenging large clot burdens in proximal vessels. Such technological leaps improve clinical outcomes and clinician confidence, thereby fostering wider adoption. This impact is reflected in market performance, with Penumbra, a prominent thrombectomy device manufacturer, reporting global thrombectomy revenue of $253.9 million in the first quarter of 2026.

Download Free Sample Report

Key Market Challenges

The substantial capital investment necessary for neurothrombectomy devices and specialized infrastructure presents a significant barrier to the expansion of the global market. These advanced medical instruments require dedicated facilities and a high upfront financial commitment, which limits broader adoption, particularly within healthcare systems facing resource limitations. According to a September 2024 policy paper co-published by the World Stroke Organization and Philips, a clear recommendation exists to expand and invest in capital infrastructures specifically for advanced stroke services like mechanical thrombectomy, underscoring this ongoing need.

Furthermore, the requirement for highly skilled neurointerventionalists adds another layer to this challenge. The extensive training and specialization needed for these medical professionals involve considerable costs, directly impacting their availability and the scalability of neurothrombectomy programs. For instance, the European Society of Minimally Invasive Neurological Therapy (ESMINT) offers a Skills Training course in 2026 with a fee of €850, representing a component of specialized neurointerventional education. This financial outlay for human resources, coupled with equipment and infrastructure expenses, significantly restricts wider market penetration and patient access globally.

Key Market Trends

The global neurothrombectomy devices market is significantly influenced by the accelerating integration of artificial intelligence in stroke detection and triage. This trend is enhancing the efficiency of patient identification and selection for thrombectomy procedures by rapidly analyzing medical images and patient data. AI-powered platforms facilitate faster diagnosis of large vessel occlusions, which are critical for timely intervention. For instance, a Viz.ai study presented at the International Stroke Conference 2026 demonstrated a 44% reduction in door-in-door-out time for stroke patients, highlighting AI's impact on streamlining transfer protocols and accelerating access to specialized care. This expedited workflow improves patient outcomes and expands the window for effective treatment, thereby driving demand for neurothrombectomy devices.

Concurrently, the expansion of telestroke networks and remote diagnosis capabilities represents another pivotal trend, addressing geographical disparities in stroke care access. These networks connect patients in remote or underserved areas with neurological specialists, enabling timely evaluation and treatment decisions. This capability is crucial in situations where on-site expertise is limited, directly influencing the utilization of neurothrombectomy devices by expanding the eligible patient population for mechanical thrombectomy. According to a May 2026 article by FinancialContent, Hendry Regional Medical Center, a Critical Access Hospital, achieved a 30% reduction in door-to-needle time from 2022 to 2025 through its teleneurology program, showcasing how remote consultation can significantly improve treatment delivery times in facilities that previously lacked immediate neurologist access. Such advancements contribute to increased procedure volumes and market growth by overcoming logistical barriers to specialized stroke intervention.

Segmental Insights

The Clot Retrievers segment stands out as the fastest-growing within the Global Neurothrombectomy Devices Market due to its significant advancements in acute ischemic stroke treatment. These devices have revolutionized procedures by mechanically removing blood clots, thereby enhancing efficacy and improving patient outcomes through more effective clot retrieval and greater recanalization rates. The increasing prevalence of acute ischemic stroke globally, coupled with a growing body of clinical studies demonstrating reduced disability and mortality, has led to their broader adoption as a standard treatment by healthcare professionals. Ongoing product innovation and strategic launches by manufacturers further solidify this segment's rapid expansion.

Regional Insights

North America is the dominant region in the Global Neurothrombectomy Devices Market due to a combination of factors. The high prevalence of acute ischemic stroke and related risk factors significantly drives demand. This region benefits from advanced healthcare infrastructure, including numerous specialized stroke centers and substantial investments in research and development by key market players. Furthermore, strong reimbursement policies and increased government initiatives aimed at stroke awareness and treatment facilitate the widespread adoption of neurothrombectomy procedures, cementing North America's leading position.

Recent Developments

• In April 2026, Rapid Medical received U.S. Food and Drug Administration (FDA) clearance for its TIGERTRIEVER 25 thrombectomy device. This new addition expanded the company's suite of tools designed for treating acute ischemic stroke caused by large vessel occlusion. The TIGERTRIEVER 25, part of the broader TIGERTRIEVER platform, was specifically engineered to address large clot burdens in proximal vessels, such as the internal carotid artery and M1 segment, which are often challenging to treat during stroke intervention procedures. The device's clearance aims to provide physicians with enhanced flexibility in managing various anatomical and clinical scenarios in stroke care.
• In March 2026, Johnson & Johnson MedTech officially launched three new devices as part of its aspiration-first stroke portfolio: the Cereglide 42 and Cereglide 57 aspiration catheters, and the Innerglide 7 delivery aid. These devices were developed to assist clinicians in reaching and removing distal clots that are associated with significant pain and swelling in stroke patients. The Cereglide catheters incorporate proprietary technology for both support and flexibility, aiding in targeting challenging thrombi. The Innerglide 7 delivery aid was designed to guide large-bore catheters, improving navigation and reducing resistance in complex anatomy.
• In March 2026, XCath, a medical device company focusing on neuro-endovascular surgical robotics, secured $30 million in Series C funding. This investment supports the company's ongoing efforts to commercialize its endovascular robotic system and to conduct a clinical telerobotic mechanical thrombectomy. This funding followed XCath's successful first-in-human procedures in November 2025, where its Iris robotic system was used to treat patients with complex brain aneurysms. The Iris system is distinguished as the only endovascular robotic system currently in development to achieve intracranial navigation and operate with standard monoplane imaging equipment, aiming to expand access to life-saving neurovascular care.
• In February 2026, Rapid Medical announced the latest findings from its multicenter, randomized controlled DISTALS trial. The study demonstrated that the company's TIGERTRIEVER 13 device achieved superior brain tissue reperfusion with an excellent safety profile. This was observed when compared to medical management in patients experiencing medium vessel occlusion (MVO) stroke. These results were presented at the 2026 International Stroke Conference, indicating that the TIGERTRIEVER 13, designed to actively adjust to vessel anatomy, could offer a viable option for a previously underserved stroke population, which accounts for nearly half of all ischemic strokes.

Key Market Players

• Medtronic plc
• Stryker Corporation
• Imperative Care, Inc.
• Penumbra, Inc.
• Terumo Corporation
• MicroPort Scientific Corporation
• Phenox GmbH
• Acandis GmbH
• BALT Group
• Route 92 Medical, Inc.

By Product	By End User	By Region
Clot Retrievers Aspiration/ Suction Devices Vascular Snares	Hospital Emergency Clinics Ambulatory Surgical Centers	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Neurothrombectomy Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Neurothrombectomy Devices Market, By Product:

• Clot Retrievers
• Aspiration/ Suction Devices
• Vascular Snares

• Neurothrombectomy Devices Market, By End User:

• Hospital
• Emergency Clinics
• Ambulatory Surgical Centers

• Neurothrombectomy Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE